05:02 , Jan 19, 2018 |  BC Week In Review  |  Company News

Context acquires onapristone from Arno

Cancer company Context Therapeutics (Philadelphia, Pa.) acquired worldwide rights to Apristor onapristone XR from Arno Therapeutics Inc. (Flemington, N.J.) for an undisclosed one-time payment. In December, Arno announced that it would dissolve and turn over...
20:32 , Feb 16, 2017 |  BC Week In Review  |  Company News

NexImmune deal

An investor group acquired immuno-oncology company NexImmune for an undisclosed amount. The group includes Sol Barer, former Celgene Corp. (NASDAQ:CELG, Summit, N.J.) chairman and CEO and current chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel...
18:08 , Feb 14, 2017 |  BC Extra  |  Financial News

Barer among investors acquiring NexImmune

An investor group including former CEOs of Celgene Corp. (NASDAQ:CELG) and Medtronic plc (NYSE:MDT) has acquired immuno-oncology company NexImmune Inc. (Gaithersburg, Md.) for an undisclosed amount. The group includes Sol Barer, the former Celgene chairman and...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Advising Israel

BC Staff  A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
07:00 , Jun 9, 2016 |  BC Innovations  |  Strategy

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer  Five years after taking the helm as Sanofi's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment of Yong-Jun...
07:00 , Jun 8, 2015 |  BioCentury  |  Emerging Company Profile

Financing innovation in China

Yabao Pharmaceutical Group Co. Ltd. is seeking VCs to join it in financing a new spinout that has aspirations to participate in global development of novel drugs. Newco Suzhou Yabao Pharmaceutical R&D Co. Ltd. is...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Viral protein 1 (VP1)

Infectious disease INDICATION: Enterovirus In vitro studies suggest the antiviral compound pleconaril could help treat enterovirus 68 (EV68) infection. In a cell-based assay, pleconaril inhibited the activity of the Fermon CA62-1 strain of EV68 at an EC50...
08:00 , Feb 2, 2015 |  BioCentury  |  Politics, Policy & Law

Dr. Califf goes to Washington

FDA has had three deputy commissioners during the Obama administration;each was expected to play a major role in shaping the agency, and none of them lived up to expectations. Last week's announcement that Robert Califf...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase-4 (PDE-4); fragile X mental retardation 1 (FMR1)

Neurology INDICATION: Fragile X syndrome Mouse and fly studies suggest that PDE-4 inhibitors could help treat cognitive impairment in patients with fragile X syndrome. In a fly model of fragile X syndrome, cAMP levels in the head...
02:27 , Dec 18, 2014 |  BC Extra  |  Clinical News

Well-traveled desmoteplase finally hits the wall

H. Lundbeck A/S (CSE:LUN) said it will cease development of desmoteplase (DPSA) to treat acute ischemic stroke. The compound, which has been in development for more than a decade and failed a Phase III study...